



## Pliant Therapeutics to Participate in Upcoming Investor Conferences

February 24, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, will participate in the following conferences in March.

- **Cowen 42<sup>nd</sup> Annual Health Care Conference:** Dr. Coulie will participate in the Respiratory/ Infections panel on Tuesday, March 8, at 2:10 p.m. ET / 11:10 a.m. PT
- **Oppenheimer 32<sup>nd</sup> Annual Healthcare Conference:** Dr. Coulie will present a company update on Wednesday, March 16, at 3:20 p.m. ET / 12:20 p.m. PT

Interested parties can access these presentations from the Investor Relations' Events & Presentation page of Pliant's website at <https://ir.pliantx.com/news-and-events/events-and-presentations> with an audio archive available for 30 days from the time they are made available.

### About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of  $\alpha_v\beta_6$  and  $\alpha_v\beta_1$  integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of  $\alpha_v\beta_1$  for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit [www.pliantx.com](http://www.pliantx.com) and follow us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

### Investor and Media Contact:

Christopher Keenan  
Vice President, Investor Relations and Corporate Communications  
Pliant Therapeutics, Inc.  
[ir@pliantrx.com](mailto:ir@pliantrx.com)